SavedAdd your journal

Journals / Türk Toraks Dergisi / 2008 / Cilt: 9 - Sayı: 3

Tümör nekrozis faktör-α inhibitörleri ile tedavi komplikasyonu olan iki tüberküloz olgusu

Two cases of tuberculosis complicating treatment with tumor necrosis factor-α inhibitors

MUKADDER ÇALIKOĞLU
Günşah ŞAHİN
Gönül ASLAN
Pages
133–136
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Physicians should be aware of the risk of the reactivation of TB, despite isoniazid chemoprophylaxis, with unusual clinical manifestations and a paradoxical response.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:TNF-α blocking agents have been increasingly used in the treatment of systemic inflammatory diseases.
📊
Key Findings & Data:In this paper we described two cases of TNF-α inhibitor-associated TB.
💡
Conclusion & Impact:Physicians should be aware of the risk of the reactivation of TB, despite isoniazid chemoprophylaxis, with unusual clinical manifestations and a paradoxical response.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tüberküloz · Erkek · Erişkin

Abstract

TNF-α blocking agents have been increasingly used in the treatment of systemic inflammatory diseases. The main adverse effect of these drugs is susceptibility to infections, mainly reactivation of latent tuberculous infection (LTBI). In this paper we described two cases of TNF-α inhibitor-associated TB. Because LTBI and BCG vaccination are widespread in the Turkish population, a stringent pre-treatment screening protocol for LTBI should be used. In such patients, TB frequently presents as an extrapulmonary or disseminated and life-threatening disease. Physicians should be aware of the risk of the reactivation of TB, despite isoniazid chemoprophylaxis, with unusual clinical manifestations and a paradoxical response.

Özet

TNF-α bloke edici ajanlar sistemik inflamatuvar hastalıkların tedavisinde artan bir şekilde kullanılmaktadır. Bu ilaçların temel yan etkisi başta latent tüberküloz (LTBİ) olmak üzere infeksiyonlara duyarlılıktır. Bu makalede TNF-α inhibitörleri ile ilişkili iki olguyu tanımladık. Türk halkında LTBİ ve BCG aşılaması yaygın olması nedeniyle tedavi öncesi dikkatli bir LTBİ tarama protokolü kullanılmalıdır. Bu hastalarda tüberküloz sıklıkla ekstrapulmoner veya yaygın ve hayatı tehtid eden bir hastalık olarak ortaya çıkar. Klinisyenler izoniazid ile koruyucu tedaviye karşın LTBI reaktivasyonu riski, hastalığın sık izlenmeyen klinik formları ve paradoksal yanıt açısından uyanık olmalıdır.

🔖

Cite This Article

ÇALIKOĞLU, M., ŞAHİN, G., ASLAN, G. (2008). Tümör nekrozis faktör-α inhibitörleri ile tedavi komplikasyonu olan iki tüberküloz olgusu. Türk Toraks Dergisi, Cilt: 9 - Sayı: 3, 133–136. https://ajindex.com/articles/329594

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Vlachaki E, Phastakis K, Tsintiris K, et al. Delayed response to anti tuberculosis treatment in a patient on infliximab. Respir Med 2005;99:648-52
  2. Gaemperli A, Hauser T, Speck R. Risk of infection during treatment with tumor necrosis factor-alpha inhibitors. Z Rheumatol 2006;65:24-8,30-1
  3. Kroesen S, Widmer AF, Tyndall A, et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 2003;42:617-21
  4. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
  5. Mutlu GM, Mutlu EA, Bellmeyer A, et al. Pulmonary adverse events of anti Tumor Necrosis Factor-α antibody therapy. Am. J Med 2006;119:639-46
  6. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
  7. Long R, Gardam M. Tumor necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6
  8. Kaene J. TNF-blocking agents and tuberculosis: new drugs illuminate and old topic. Rheumatology 2005; 44:714-20
  9. A guide to prevent tuberculosis in patients receiving anti TNF agents. II. Society of Rheumatismal Research and Education Concensus meeting report (Turkish) 2005 May 7; İzmir. http://www.romatoloji.org Accessed 20,2005 10) Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;36:1168-73
  10. Brock I, Weldingh K, Lilleback T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9
  11. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001;286:1740-7
  12. Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-32
  13. Ruiz JP, Centeno NO, Alvarez ER, et al. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol 2003;30:1657-8
  14. O'Brien RJ. Preventive therapy of tuberculosis. In: Porter JDH, McAdam KPWJ, eds. Tuberculosis: back to the future. Chiehester, UK: John Wiley S